Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine vs Investigator's Choice in Relapsed/Refractory AITL
NCT03703375Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azacitidine in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Celgene Corporation. Started Nov 2018; status: completed.
02
Drugs
azacitidine
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT03703375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703375.